PURPOSE: The aim of this study was to combine clinical pathologic variables that are associated with pathologic completer response (pCR) and relapse-free survival (RFS) after neoadjuvant chemotherapy into prediction nomograms. METHODS: A total of 370 stage II or III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. We developed the nomograms using logistic regression model for pCR and Cox proportional hazard regression model for RFS. RESULTS: The nomogram for pCR based on initial tumor size, estrogen receptor (ER), human epidermal growth factor receptor 2, and Ki67 had good discrimination performance (AUROC = 0.830). Multivariate Cox model identified age less than 35, initial clinical stage, pathologic stage, ER, Ki67 as prognostic factors, and the nomogram for RFS was developed based on these covariates. The concordance index for the second nomogram was 0.781, and calibration was also good. CONCLUSIONS: We developed nomograms based on clinical and pathologic characteristics to predict the probability of pCR and RFS for patients receiving neoadjuvant docetaxel/doxorubicin chemotherapy.
PURPOSE: The aim of this study was to combine clinical pathologic variables that are associated with pathologic completer response (pCR) and relapse-free survival (RFS) after neoadjuvant chemotherapy into prediction nomograms. METHODS: A total of 370 stage II or III breast cancerpatients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. We developed the nomograms using logistic regression model for pCR and Cox proportional hazard regression model for RFS. RESULTS: The nomogram for pCR based on initial tumor size, estrogen receptor (ER), humanepidermal growth factor receptor 2, and Ki67 had good discrimination performance (AUROC = 0.830). Multivariate Cox model identified age less than 35, initial clinical stage, pathologic stage, ER, Ki67 as prognostic factors, and the nomogram for RFS was developed based on these covariates. The concordance index for the second nomogram was 0.781, and calibration was also good. CONCLUSIONS: We developed nomograms based on clinical and pathologic characteristics to predict the probability of pCR and RFS for patients receiving neoadjuvant docetaxel/doxorubicin chemotherapy.
Authors: Roman Rouzier; Lajos Pusztai; Jean-Remi Garbay; Suzette Delaloge; Kelly K Hunt; Gabriel N Hortobagyi; Donald Berry; Henry M Kuerer Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: Quing Zhu; Liqun Wang; Susan Tannenbaum; Andrew Ricci; Patricia DeFusco; Poornima Hegde Journal: Breast Cancer Res Date: 2014-10-28 Impact factor: 6.466
Authors: Hyuk Hur; Min Soo Cho; Woong Sub Koom; Joon Seok Lim; Tae Il Kim; Joong Bae Ahn; Hoguen Kim; Nam Kyu Kim Journal: Chin J Cancer Res Date: 2020-04 Impact factor: 5.087
Authors: Seung Pil Jung; Sung Mo Hur; Se Kyung Lee; Sangmin Kim; Min-Young Choi; Soo Youn Bae; Jiyoung Kim; Min Kuk Kim; Won Ho Kil; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim; Seok Jin Nam; Jeoung Won Bae; Jeong Eon Lee Journal: J Breast Cancer Date: 2013-03-31 Impact factor: 3.588